The UK and US have concluded a major commercial pact that will ensure no tariffs on UK medicine products going into the US market.
The Terms of the Accord
As part of the deal, the UK has pledged to raise expenditure on drugs through the NHS. This move secures that tariffs on these key products will stay at zero for a period of the next three years.
This agreement follows previous threats to hike tariffs on patented pharmaceutical products, with increases mentioned up to 100%.
"This deal between the United Kingdom bolsters the international landscape for innovative medicines and brings long-overdue equity to American-British pharmaceutical trade," a release said.
Economic Importance
Medicines represent one of the Britain's biggest exports to the United States, which is by far the biggest market for major companies like GSK and AstraZeneca.
Statistics reveal that in the year to the end of last September, the UK exported medicines totaling billions to the US. This value made up 17.4% of total UK exports in that timeframe.
"This guarantee secures jobs, boosts investment and paves the way for the UK to become a worldwide center for medical research," the Business and Trade Secretary remarked.
Detailed British Pledges
The agreement includes several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to increase overall public funding on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates exceeded 20%.
Broader Context
This agreement takes place against a protracted tension between the drug companies and the British authorities over drug pricing and approval rates.
These tensions were exacerbated by claims that American consumers were charged several times more for the identical medicines than patients in the other developed nations.
Recently, several significant manufacturing plans in the UK have been paused or scrapped, while major expansions have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
